Nature Chemical Biology, Journal Year: 2024, Volume and Issue: 21(1), P. 22 - 23
Published: Dec. 24, 2024
Language: Английский
Cell chemical biology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
1
Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
0
Nature reviews. Cancer, Journal Year: 2025, Volume and Issue: unknown
Published: April 25, 2025
Language: Английский
Citations
0
ACS Chemical Biology, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 12, 2024
Targeted protein degradation (TPD) is an emerging pharmacologic strategy. It relies on small-molecule "degraders" that induce proximity of a component E3 ubiquitin ligase complex and target to ubiquitination subsequent proteasomal degradation. Essentially, degraders thus expand the function ligases, allowing them degrade proteins they would not recognize in absence small molecule. Over past decade, insights gained from identifying, designing, characterizing various have significantly enhanced our understanding TPD mechanisms, precipitating rational degrader discovery strategies. In this Account, I aim explore how these can be extrapolated anticipate both opportunities challenges utilizing overarching concept proximity-inducing pharmacology manipulate other cellular circuits for dissection biological mechanisms therapeutic purposes.
Language: Английский
Citations
3
Cell chemical biology, Journal Year: 2024, Volume and Issue: 31(9), P. 1688 - 1698
Published: Sept. 1, 2024
Language: Английский
Citations
3
Cell chemical biology, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 1, 2024
Language: Английский
Citations
3
Progress in medicinal chemistry, Journal Year: 2024, Volume and Issue: unknown, P. 61 - 160
Published: Jan. 1, 2024
Language: Английский
Citations
1
RSC Medicinal Chemistry, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 29, 2024
Target 2035 is a global initiative that seeks to identify pharmacological modulator of most human proteins by the year 2035. As part an ongoing series annual updates this initiative, we summarise here efforts EUbOPEN project whose objectives and results are making strong contribution goals public-private partnership with four pillars activity: (1) chemogenomic library collections, (2) chemical probe discovery technology development for hit-to-lead chemistry, (3) profiling bioactive compounds in patient-derived disease assays, (4) collection, storage dissemination project-wide data reagents. The substantial outputs programme include compound covering one third druggable proteome, as well 100 probes, both profiled patient derived hundreds sets deposited existing public repositories project-specific resource exploring outputs.
Language: Английский
Citations
1
ACS Medicinal Chemistry Letters, Journal Year: 2024, Volume and Issue: 15(7), P. 998 - 1000
Published: June 22, 2024
The continuous pursuit of novel therapeutic approaches to modulate biological processes and combat diseases such as cancer has led significant advancements in protein degradation. This Patent Highlight reviews three recent patents introducing innovative compositions methods enhance enzyme activity target These present groundbreaking the development glutarimide-containing compounds Protein-Protein Interaction Targeted Chimeras (PPI-TACs) aimed at improving interventions' efficacy, selectivity, stability.
Language: Английский
Citations
0
Cell chemical biology, Journal Year: 2024, Volume and Issue: 31(8), P. 1391 - 1393
Published: Aug. 1, 2024
Language: Английский
Citations
0